We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01675154
Recruitment Status : Terminated (Due to unavailability of the drug.)
First Posted : August 29, 2012
Results First Posted : August 19, 2021
Last Update Posted : August 19, 2021
Sponsor:
Information provided by (Responsible Party):
Abhimanyu Garg, University of Texas Southwestern Medical Center

Tracking Information
First Submitted Date  ICMJE August 27, 2012
First Posted Date  ICMJE August 29, 2012
Results First Submitted Date  ICMJE May 21, 2021
Results First Posted Date  ICMJE August 19, 2021
Last Update Posted Date August 19, 2021
Actual Study Start Date  ICMJE November 2015
Actual Primary Completion Date June 30, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 26, 2021)
  • Serum Triglycerides at First Intervention Period [ Time Frame: 4 weeks after the assigned treatment (first intervention period) ]
    Serum triglyceride level will be measured after taking each assigned intervention at first intervention period.
  • Serum Triglycerides at Second Intervention Period [ Time Frame: 4 weeks after the assigned treatment (Second Intervention Period) ]
    Serum triglyceride level will be measured after taking each assigned intervention at second intervention period
  • Serum Triglycerides at Third Intervention Period [ Time Frame: 4 weeks after the assigned treatment (Third Intervention Period) ]
    Serum triglyceride level will be measured after taking each assigned intervention at intervention period
  • Serum Triglycerides at Fourth Intervention Period [ Time Frame: 4 weeks after the assigned treatment (Fourth Intervention Period) ]
    Serum triglyceride level will be measured after taking each assigned intervention at fourth intervention period
Original Primary Outcome Measures  ICMJE
 (submitted: August 28, 2012)
Change in serum triglycerides from baseline for each crossover arm phase of placebo/placebo, orlistat/placebo, orlistat/SLx-4090, SLx-4090/placebo [ Time Frame: Every every 4 weeks at the end of each phase for 3 draws ]
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia
Official Title  ICMJE Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia
Brief Summary

Funding Source - FDA OOPD

This study is being done to find out whether an investigational (not approved by FDA ) drug called SLx-4090 or Orlistat (FDA approved medication for weight loss) when given alone or in combination can treat the high blood fat (elevated triglycerides)levels found in the condition Type 1 Hyperlipoproteinemia (T1HLP) better or more safely than low fat diet alone, the current standard medical care.

It is also not clear whether Orlistat, that is FDA approved for weight loss, is effective in lowering blood fat levels in patients with Type 1 hyperlipoproteinemia (T1HLP). The researchers are interested in learning whether any one of these drugs when given alone or in combination is more effective and safe in treating T1HLP.

Detailed Description

Type I hyperlipoproteinemia is a rare, autosomal recessive metabolic disorder characterized by extreme hypertriglyceridemia due to a deficiency in lipoprotein lipase or related proteins. Treatment of these patients is challenging as triglyceride-lowering medications are ineffective. A low fat diet is helpful, however, despite good dietary compliance, some patients continue to have severe hypertriglyceridemia and recurrent pancreatitis which can be life threatening. Therefore, we wish to investigate whether inducing dietary fat malabsorption or inhibiting chylomicron formation will cause further lowering of serum triglycerides (TG) beyond the effect of limiting dietary fat intake.

We will study the efficacy and safety of an inhibitor of intestinal lipase (Orlistat) and an intestinal-specific inhibitor of microsomal triglyceride transport protein (MTP) involved in the assembly and secretion of chylomicrons (SLx-4090), alone and in combination, for reducing serum triglyceride levels in patients with Type I hyperlipoproteinemia. We plan to enroll 20 patients with Type I hyperlipoproteinemia in a randomized, double-blind, placebo-controlled, cross-over trial. After a baseline evaluation, the subjects will be randomly assigned to placebo/placebo, Orlistat/placebo, SLx-4090/placebo or Orlistat/SLx-4090 for the duration of four weeks followed by a one week wash out period. During the last week of each study period, fasting blood samples will be drawn for three consecutive days for serum lipids and chemistry panel. The primary endpoint will be serum triglycerides; the secondary endpoint variables will be fasting and postprandial serum chylomicron-TG levels, postprandial serum TG levels during a meal tolerance test and retinyl palmitate levels during a meal tolerance test. Repeated measures analysis of variance will be used for statistical comparisons.

Our results may help in designing novel therapeutic approaches for patients with Type 1 hyperlipoproteinemia.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:
This trial is adaptive design/flexible design. The participants were randomized from the start of the study
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Type 1 Hyperlipoproteinemia
Intervention  ICMJE
  • Drug: SLx-4090 placebo
    Given for 4 weeks
  • Drug: Orlistat Placebo
    Given for 4 weeks
  • Drug: Orlistat
    Given for 4 weeks
  • Drug: Slx-4090
    Given for 4 weeks
Study Arms  ICMJE
  • Placebo Comparator: SLx-4090 placebo/Orlistat Placebo

    Slx-4090(placebo) is dosed as 4 tablets of 50 mg, three times per day with meals.

    Orlistat (placebo) is dosed as 2 capsules of 60 mg, three times per day with meals.

    This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment.

    Interventions:
    • Drug: SLx-4090 placebo
    • Drug: Orlistat Placebo
  • Experimental: Orlistat/placebo
    Orlistat two capsules 60mg each, three times per day with meals. Placebo for SLx-4090, 4 tablets 50mg each, three times per day with meals. This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment.
    Interventions:
    • Drug: SLx-4090 placebo
    • Drug: Orlistat
  • Experimental: Orlistat placebo /SLx-4090
    Orlistat placebo 2 capsules, 60mg each three times per day with meals. Slx-4090 4 tablets, 50mg each. three times per day with meals. This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment.
    Interventions:
    • Drug: Orlistat Placebo
    • Drug: Slx-4090
  • Experimental: Orlistat/SLx-4090
    Orlistat, 2 capsules 60 mg each, three times per day with meals. SLx-4090 4 tablets 50mg each, three times per day with meals. This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment.
    Interventions:
    • Drug: Orlistat
    • Drug: Slx-4090
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: September 25, 2020)
5
Original Estimated Enrollment  ICMJE
 (submitted: August 28, 2012)
20
Actual Study Completion Date  ICMJE June 30, 2020
Actual Primary Completion Date June 30, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Type I hyperlipoproteinemia.
  • Fasting serum triglyceride levels of greater than 1000 mg/dL.
  • Age > 12 years

Exclusion Criteria:

  • Secondary hypertriglyceridemias due to diabetes, renal disease, hypothyroidism, alcoholism and drug therapy such as estrogens and estrogen analogues, steroids, HIV-protease inhibitors, retinoic acid derivatives and interferons.
  • Pregnant or lactating women
  • Significant liver disease (elevated transaminases > 2 times upper limit of normal)
  • Alcohol abuse (> 7 drinks or 84 g per week for women and > 14 drinks for men or 168 g per week for men)
  • Drug use (cocaine, marijuana, LSD, etc.)
  • Major surgery in the past three months
  • Congestive heart failure
  • Serum creatinine greater than 2.5 mg/dL
  • Cancer within the past five years
  • Gastrointestinal surgery in the past
  • Current therapy with anti-coagulants, digoxin and anti-arrhythmics
  • Chronic malabsorption syndromes
  • Cholestasis
  • Acute illnesses such as acute pancreatitis in the last 8 weeks
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 12 Years to 100 Years   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01675154
Other Study ID Numbers  ICMJE 3940
FD-R-003940
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Abhimanyu Garg, University of Texas Southwestern Medical Center
Original Responsible Party University of Texas Southwestern Medical Center
Current Study Sponsor  ICMJE University of Texas Southwestern Medical Center
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Abhimanyu Garg, MD UT Southwestern Medical Center
PRS Account University of Texas Southwestern Medical Center
Verification Date July 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP